Trastuzumab in Treating Patients With Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00003740

Run by

Memorial Sloan Kettering Cancer Center

Starts

1998-10-01

Expected to finish

2002-09-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.